Addiction Medicine
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock insights into global addiction medicine markets. Stay ahead with pharma intelligence for BD, investment, and regulatory strategy.
Showing 1–2 of 2 articles
Quick answer
NovaPharmaNews Addiction Medicine hub for FDA covers 2 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Clearmind Medicine CMND-100 Meets Primary Safety Endpoint in Alcohol Use Disorder Trial
FDA Approves First OTC Naloxone Nasal Spray for Opioid Overdose
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.